IBDEI0G2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7426,0)
 ;;=R63.3^^30^408^76
 ;;^UTILITY(U,$J,358.3,7426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7426,1,3,0)
 ;;=3^Feeding Difficulties
 ;;^UTILITY(U,$J,358.3,7426,1,4,0)
 ;;=4^R63.3
 ;;^UTILITY(U,$J,358.3,7426,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,7427,0)
 ;;=R63.4^^30^408^29
 ;;^UTILITY(U,$J,358.3,7427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7427,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,7427,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,7427,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,7428,0)
 ;;=R63.5^^30^408^28
 ;;^UTILITY(U,$J,358.3,7428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7428,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,7428,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,7428,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,7429,0)
 ;;=R64.^^30^408^47
 ;;^UTILITY(U,$J,358.3,7429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7429,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,7429,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,7429,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,7430,0)
 ;;=R68.3^^30^408^52
 ;;^UTILITY(U,$J,358.3,7430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7430,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,7430,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,7430,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,7431,0)
 ;;=R73.01^^30^408^96
 ;;^UTILITY(U,$J,358.3,7431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7431,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,7431,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,7431,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,7432,0)
 ;;=R73.02^^30^408^97
 ;;^UTILITY(U,$J,358.3,7432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7432,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,7432,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,7432,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,7433,0)
 ;;=R73.09^^30^408^15
 ;;^UTILITY(U,$J,358.3,7433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7433,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,7433,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,7433,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,7434,0)
 ;;=R73.9^^30^408^91
 ;;^UTILITY(U,$J,358.3,7434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7434,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,7434,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,7434,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,7435,0)
 ;;=R76.11^^30^408^150
 ;;^UTILITY(U,$J,358.3,7435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7435,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,7435,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,7435,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,7436,0)
 ;;=R79.1^^30^408^3
 ;;^UTILITY(U,$J,358.3,7436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7436,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,7436,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,7436,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,7437,0)
 ;;=R82.5^^30^408^73
 ;;^UTILITY(U,$J,358.3,7437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7437,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,7437,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,7437,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,7438,0)
 ;;=R82.6^^30^408^26
 ;;^UTILITY(U,$J,358.3,7438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7438,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,7438,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,7438,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,7439,0)
 ;;=R82.7^^30^408^27
 ;;^UTILITY(U,$J,358.3,7439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7439,1,3,0)
 ;;=3^Abnormal Urine Microbiological Findings
 ;;^UTILITY(U,$J,358.3,7439,1,4,0)
 ;;=4^R82.7
